Azithromycin Treatment Alters Gene Expression in Inflammatory, Lipid Metabolism, and Cell Cycle Pathways in Well-Differentiated Human Airway Epithelia

Prolonged macrolide antibiotic therapy at low doses improves clinical outcome in patients affected with diffuse panbronchiolitis and cystic fibrosis. Consensus is building that the therapeutic effects are due to anti-inflammatory, rather than anti-microbial activities, but the mode of action is likely complex. To gain insights into how the macrolide azithromycin (AZT) modulates inflammatory responses in airways, well-differentiated primary cultures of human airway epithelia were exposed to AZT alone, an inflammatory stimulus consisting of soluble factors from cystic fibrosis airways, or AZT followed by the inflammatory stimulus. RNA microarrays were conducted to identify global and specific gene expression changes. Analysis of gene expression changes revealed that the AZT treatment alone altered the gene profile of the cells, primarily by significantly increasing the expression of lipid/cholesterol genes and decreasing the expression of cell cycle/mitosis genes. The increase in cholesterol biosynthetic genes was confirmed by increased filipin staining, an index of free cholesterol, after AZT treatment. AZT also affected genes with inflammatory annotations, but the effect was variable (both up- and down-regulation) and gene specific. AZT pretreatment prevented the up-regulation of some genes, such as MUC5AC and MMP9, triggered by the inflammatory stimulus, but the up-regulation of other inflammatory genes, e.g., cytokines and chemokines, such as interleukin-8, was not affected. On the other hand, HLA genes were increased by AZT. Notably, secreted IL-8 protein levels did not reflect mRNA levels, and were, in fact, higher after AZT pretreatment in cultures exposed to the inflammatory stimulus, suggesting that AZT can affect inflammatory pathways other than by altering gene expression. These findings suggest that the specific effects of AZT on inflamed and non-inflamed airway epithelia are likely relevant to its clinical activity, and their apparent complexity may help explain the diverse immunomodulatory roles of macrolides.

[1]  D. Griffith,et al.  The effect of azithromycin and clarithromycin on ex vivo interleukin-8 (IL-8) release from whole blood and IL-8 production by human alveolar macrophages. , 2001, The Journal of antimicrobial chemotherapy.

[2]  M. d’Yvoire,et al.  Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin. , 1998, The Journal of antimicrobial chemotherapy.

[3]  M. Parnham,et al.  Modulation of neutrophil and inflammation markers in chronic obstructive pulmonary disease by short-term azithromycin treatment. , 2005, European journal of pharmacology.

[4]  A. Bush,et al.  Anti‐inflammatory effects of macrolides in lung disease * , 2001, Pediatric pulmonology.

[5]  B. Rubin,et al.  Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. , 2006, American journal of physiology. Lung cellular and molecular physiology.

[6]  K. Yanagihara,et al.  Different effects of telithromycin on MUC5AC production induced by human neutrophil peptide-1 or lipopolysaccharide in NCI-H292 cells compared with azithromycin and clarithromycin. , 2008, The Journal of antimicrobial chemotherapy.

[7]  今村 圭文 Azithromycin inhibits MUC5AC production induced by the Pseudomonas aeruginosa autoinducer N-(3-oxododecanoyl) homoserine lactone in NCI-H292 cells , 2005 .

[8]  M. Hentzer,et al.  Azithromycin Blocks Quorum Sensing and Alginate Polymer Formation and Increases the Sensitivity to Serum and Stationary-Growth-Phase Killing of Pseudomonas aeruginosa and Attenuates Chronic P. aeruginosa Lung Infection in Cftr−/− Mice , 2007, Antimicrobial Agents and Chemotherapy.

[9]  B. A. Janowski The hypocholesterolemic agent LY295427 up-regulates INSIG-1, identifying the INSIG-1 protein as a mediator of cholesterol homeostasis through SREBP , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  W. Busse,et al.  Increased matrix metalloproteinase-9 in the airway after allergen challenge. , 2000, American journal of respiratory and critical care medicine.

[11]  S. Ohno,et al.  Macrolides inhibit epithelial cell-mediated neutrophil survival by modulating granulocyte macrophage colony-stimulating factor release. , 2004, American journal of respiratory cell and molecular biology.

[12]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[13]  H. Saito,et al.  Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells. , 2000, American journal of respiratory cell and molecular biology.

[14]  J. Ericsson,et al.  Hyperphosphorylation regulates the activity of SREBP1 during mitosis. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Standiford,et al.  Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. , 2004, American journal of respiratory and critical care medicine.

[16]  A. Mankin,et al.  Macrolide myths. , 2008, Current opinion in microbiology.

[17]  R. Scott,et al.  Clarithromycin targets neutrophilic airway inflammation in refractory asthma. , 2008, American journal of respiratory and critical care medicine.

[18]  I. Stamenkovic,et al.  Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. , 2000, Genes & development.

[19]  E. Tagaya,et al.  Effect of clarithromycin on sputum production and its rheological properties in chronic respiratory tract infections , 1995, Antimicrobial agents and chemotherapy.

[20]  Y. Ichikawa,et al.  Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients. , 1993, The American review of respiratory disease.

[21]  P. Bozza,et al.  Lipid bodies in innate immune response to bacterial and parasite infections. , 2008, International immunopharmacology.

[22]  B. Rubin,et al.  Clarithromycin has an immunomodulatory effect on ERK-mediated inflammation induced by Pseudomonas aeruginosa flagellin. , 2007, The Journal of antimicrobial chemotherapy.

[23]  J. Clancy,et al.  Matrix metalloprotease-9 dysregulation in lower airway secretions of cystic fibrosis patients. , 2007, American journal of physiology. Lung cellular and molecular physiology.

[24]  F. Maxfield,et al.  Role of cholesterol and lipid organization in disease , 2005, Nature.

[25]  N. White,et al.  Mechanistic similarities between cultured cell models of cystic fibrosis and niemann-pick type C. , 2004, American journal of respiratory cell and molecular biology.

[26]  B. Rubin,et al.  Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. , 2008, Pharmacology & therapeutics.

[27]  R. Boucher,et al.  Cystic Fibrosis Airway Epithelial Ca2+i Signaling , 2005, Journal of Biological Chemistry.

[28]  M. Brown,et al.  Regulation of SREBP Processing and Membrane Lipid Production by Phospholipids in Drosophila , 2002, Science.

[29]  S. Kohno,et al.  Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. , 1996, Respiration; international review of thoracic diseases.

[30]  J. Pechère New perspectives on macrolide antibiotics. , 2001, International journal of antimicrobial agents.

[31]  T. Kohyama,et al.  Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells. , 1997, American journal of respiratory and critical care medicine.

[32]  P. E. Van den Steen,et al.  Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-alpha and leaves RANTES and MCP-2 intact. , 2000, Blood.

[33]  Y. Hirakata,et al.  Azithromycin Inhibits MUC5AC Production Induced by the Pseudomonas aeruginosa Autoinducer N-(3-Oxododecanoyl) Homoserine Lactone in NCI-H292 Cells , 2004, Antimicrobial Agents and Chemotherapy.

[34]  P. Courtoy,et al.  The macrolide antibiotic azithromycin interacts with lipids and affects membrane organization and fluidity: Studies on langmuir-blodgett monolayers, liposomes and J774 macrophages , 2003, The Journal of Membrane Biology.

[35]  A. Prince,et al.  Effects of azithromycin on clinical isolates of Pseudomonas aeruginosa from cystic fibrosis patients. , 2005, Chest.

[36]  R. Brasseur,et al.  Decrease of elastic moduli of DOPC bilayers induced by a macrolide antibiotic, azithromycin. , 2007, Biochimica et biophysica acta.

[37]  R. Davies,et al.  Effect of Haemophilus influenzae endotoxin on the synthesis of IL-6, IL-8, TNF-alpha and expression of ICAM-1 in cultured human bronchial epithelial cells. , 1994, The European respiratory journal.

[38]  D. Touw,et al.  Pharmacokinetics of Azithromycin in Plasma, Blood, Polymorphonuclear Neutrophils and Sputum During Long-Term Therapy in Patients With Cystic Fibrosis , 2006, Therapeutic drug monitoring.

[39]  S. Hodge,et al.  Azithromycin increases phagocytosis of apoptotic bronchial epithelial cells by alveolar macrophages , 2006, European Respiratory Journal.

[40]  N. Matsumori,et al.  Detailed description of the conformation and location of membrane-bound erythromycin a using isotropic bicelles. , 2006, Journal of medicinal chemistry.

[41]  G. Silverman,et al.  Intracellular and extracellular serpins modulate lung disease , 2008, Journal of Perinatology.

[42]  E. Gabazza,et al.  In vivo and in vitro effects of macrolide antibiotics on mucus secretion in airway epithelial cells. , 2003, American journal of respiratory and critical care medicine.

[43]  Kazuhiko Yamamoto,et al.  Roxithromycin Inhibits Cytokine Production by and Neutrophil Attachment to Human Bronchial Epithelial Cells In Vitro , 1998, Antimicrobial Agents and Chemotherapy.

[44]  Y. Zhen,et al.  HERG K+ channel expression-related chemosensitivity in cancer cells and its modulation by erythromycin , 2005, Cancer Chemotherapy and Pharmacology.

[45]  M. Isobe,et al.  Matrix metalloproteinase suppression induced by clarithromycin in murine cardiac allografts. , 2009, Transplantation proceedings.

[46]  A. Livraghi,et al.  The Mitochondrial Barriers Segregate Agonist-induced Calcium-dependent Functions in Human Airway Epithelia , 2003, The Journal of general physiology.

[47]  S. Sagel,et al.  Induced sputum matrix metalloproteinase‐9 correlates with lung function and airway inflammation in children with cystic fibrosis , 2005, Pediatric pulmonology.

[48]  H. Ceri,et al.  Apoptosis, oxidative metabolism and interleukin-8 production in human neutrophils exposed to azithromycin: effects of Streptococcus pneumoniae. , 2000, The Journal of antimicrobial chemotherapy.

[49]  R. Davies,et al.  Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells. , 1995, The European respiratory journal.

[50]  K. Asano,et al.  Suppression of matrix metalloproteinase production from nasal fibroblasts by macrolide antibiotics in vitro , 2004, European Respiratory Journal.

[51]  B. Rubin,et al.  Clarithromycin Delays Progression of Bronchial Epithelial Cells from G1 Phase to S Phase and Delays Cell Growth via Extracellular Signal-Regulated Protein Kinase Suppression , 2006, Antimicrobial Agents and Chemotherapy.

[52]  R. Boucher,et al.  Chronic Airway Infection/Inflammation Induces a Ca2+i-dependent Hyperinflammatory Response in Human Cystic Fibrosis Airway Epithelia* , 2005, Journal of Biological Chemistry.

[53]  Carl Alden,et al.  Biomarkers to monitor drug-induced phospholipidosis. , 2007, Toxicology and applied pharmacology.

[54]  S. Kohno,et al.  Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis. , 1994, Chest.

[55]  Satoshi Hachimura,et al.  Growth Factor-induced Phosphorylation of Sterol Regulatory Element-binding Proteins Inhibits Sumoylation, Thereby Stimulating the Expression of Their Target Genes, Low Density Lipoprotein Uptake, and Lipid Synthesis* , 2008, Journal of Biological Chemistry.

[56]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[57]  H. Saito,et al.  Effect of erythromycin on matrix metalloproteinase-9 and cell migration. , 2001, The Journal of laboratory and clinical medicine.

[58]  H. Mukae,et al.  A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis. , 1993, The American review of respiratory disease.

[59]  K. Asano,et al.  Suppression of matrix metalloproteinase-9 production from neutrophils by a macrolide antibiotic, roxithromycin, in vitro. , 2004, Mediators of inflammation.

[60]  G. Verleden,et al.  Azithromycin reduces airway neutrophilia and interleukin-8 in patients with bronchiolitis obliterans syndrome. , 2006, American journal of respiratory and critical care medicine.

[61]  M. Parnham,et al.  Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects. , 2002, European journal of pharmacology.